Can Ficicioglu, MD, PhD, is Director of the Newborn Metabolic Screening Program and the Lysosomal Storage Diseases Program, and Clinical Director of the Metabolic Disease Program at Children’s Hospital of Philadelphia. His areas of expertise include Fatty Acid Oxidation Defects, Galactosemia, Lysosomal Storage Disorders, Newborn Metabolic Screening, PKU, etc.

Dr. Can Ficicioglu completed his MD and Internship from University of Istanbul, Cerrahpasa Medical School, Istanbul, Turkey. He completed his residency from Albert Einstein Medical College, Montefiore Hospital and Medical Center, New York Medical College and St. Vincent’s Catholic Medical Center, New York followed by fellowship from Harvard Medical School and Children’s Hospital Boston. Dr. Ficicioglu is board certified in Biochemical Genetics and Pediatrics.

Representative Publications:

Pathogenesis and Treatment of Spine Disease in the Mucopolysaccharidoses

Intrafamilial Variability in the Clinical Manifestations of Mucopolysaccharidosis Type II: Data From the Hunter Outcome Survey (HOS)

Diagnostic Journey and Impact of Enzyme Replacement Therapy for Mucopolysaccharidosis IVA: A Sibling Control Study

The Effect of Idursulfase on Growth in Patients With Hunter Syndrome: Data From the Hunter Outcome Survey (HOS)

Share

Discuss in Social Wall

Share to rareTeam

Bookmark